Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TissueGene-C in Degenerative Arthritis
NCT02341391Phase 1Completed
- Sponsor
- Kolon Life Science Inc.
- Start
- Feb 2007
- Primary completion
- Aug 2008
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Invossa in osteoarthritis (OA) (3 arms), sponsored by Kolon Life Science Inc. Primary endpoint: Number of Participants with Adverse Events at 6 months. Started Feb 2007; status: completed.
02
Drugs
Invossa
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02341391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341391.